Kornimate/medical-research-clean huggingface dataset:
evaluation of root resorption during the correction of deep bite with the help of laser irradiation

Conditions: Deep Overbite

Summary: this study aims to investigate the effectiveness of low-level laser in reducing the resorption of the roots of the upper incisors. participants will be recruited from patients who will attend the department of orthodontics and dentofacial orthopaedics at damascus university. the study sample will consist of 30 patients with a deep bite who will be randomly distributed equally into two groups, 15 patients in each group, average age: 22.37±3.38 years. mini-implants will apply between the roots of the maxillary central and lateral incisor at both sides with a loading force of 40 g on each end by using a nickel-titanium spring extending from the head of the mini-implants to a wire welded to it with two hooks. a low-level laser (ga-al-as) will be used with 808 nm wavelength in continuous mode, 250 milli-watt power output, 4 joules/point energy density, 16 s per point in the experimental group. it will be applied on the day of intrusion, then on days 3,7, and 14 of the first month, and then every 15 days starting from the second month until the end of the intrusion. in addition to adjusting the force gauge every 4 weeks until the end of the intrusion stage and reaching normal coverage will be activated every 4 weeks in both groups until normal overbite was reached.

several studies have indicated the effectiveness of the lllt in accelerating orthodontic movement, but studies that have evaluated the role of this laser in reducing the risk of oiirr have been limited. moreover, the effects of laser in reducing root resorption have been studied with different types of orthodontic movements such as en masse anterior retraction, canine retraction, and tilting of the premolars before extraction, but they have not been studied with the intrusion movement

Eligibility criteria:
inclusion criteria: 1. overbite \> 4 mm 2. class i or ii molar and canine relationship malocclusion 3. maxillary anterior crowding \< 2 mm 4. maxillary incisors positioned below the functional occlusal plane 5. incisor display of 2-3 mm or more at rest 6. the facial growth pattern is normal or horizontal. exclusion criteria: 1. the maxillary incisors had a history of any trauma or endodontic treatment 2. increased inclination of the maxillary incisors towards the labial 3. the subject had any systemic disease 4. the patient exhibited poor oral hygiene

Keywords: low-level laser deep bite mini-implants root resorption
pharmacogenomics information in enhancing post-operative total joint replacement pain management: a pilot study

Conditions: Arthroplasty, Replacement, Knee; Pain, Postoperative

Summary: the objective of this study is to see how pain management and its outcomes are effected when pharmacogenomic testing is used to determine patient specific pain medication and dosing. our goal is to determine if through the use of analgesic genetic testing, tka post-operative patients will see a decrease in narcotic consumption, postsurgical opioid- related adverse reactions, and length of stay, overall nrs pain scores and while maintaining or improving their satisfaction scores.

this is a pilot study that will look at how pain management will be effected when pharmacogenomic testing is utilized to select and dose narcotic pain medications prescribed for breakthrough pain in post-operative total knee arthroplasty (tka) patients. patients will receive individualized analgesics and doses for pain mitigation based on genetic testing results. post op pain scores, narcotic consumption, adverse reactions, length of stay and patient satisfaction with pain management will be collected and analyzed to determine the significance of the pharmacogenomic analgesic testing. due to the lack of literature and evidence surrounding pharmacogenomics and its use in selecting analgesics to control post-operative pain a pilot study is being conducted to evaluate effect size (statistical variability) in an attempt to predict an appropriate sample size for a larger scale randomized control trial. the subjects enrolled and data collected for this internal pilot will be used in the larger scale parent study as well.

Eligibility criteria:
inclusion criteria: patients undergoing total knee arthroplasty patients able to understand study intent, and agree to study participation. patients with a history of preoperative narcotic dependence and/or, adverse reactions to narcotics, and/or have experienced ineffective pain management with narcotics. exclusion criteria: patients with orthopaedic and medical co-morbidities that would thwart postoperative pain control such as extra-articular pathology with referred pain to the knee (spinal stenosis, neuropathy,ipsilateral hip disease), severe knee deformity, post-traumatic and inflammatory arthritis patients with chronic pain disorders bmi \> 40 asa class \> iii gi bleed within 6 months of surgery history of drug or alcohol abuse patients unable to receive multimodal pain remitting agents including celecoxib and pregabalin. patients with diabetes and patients who are unable to receive decadron any patient receiving general anesthesia patients who will need to go to an ecf upon discharge patients who are pregnant

Keywords: orthopaedic pain management
paravertebral block (pvb) combined pectoral musculature blocks for modified radical mastectomy (mrm)

Conditions: Mastectomy, Modified Radical

Summary: previous studies have shown that pvb reduces pain and postoperative nausea and vomiting after breast cancer surgery when used in addition to general anesthesia or sedation. however, major breast cancer surgery involves areas beyond the breast tissue, such as pectoral musculature.


Eligibility criteria:
inclusion criteria: * the american society of anesthesiologists (asa) physical status classification i to iii * 20 - 75 years of age * female gender exclusion criteria: * body mass index (bmi) ≥ 35 kg/m2 * modified radical mastectomy not performed by the single surgeon (ben long yu) * anesthesia not performed by the single anesthesiologist (nai liang li)
do adolescents and adults differ in their acute response to cannabis?

Conditions: Cannabis; Cannabis Intoxication; Cannabis Use; Cannabis Dependence; Marijuana; THC; CBD; Adolescent Development

Summary: the acute effects of cannabis may differ between adolescents and adults. furthermore, these effects may be tempered by the presence of cannabidiol. this double-blind, placebo-controlled, crossover experiment investigates the acute effects of cannabis (with and without cannabidiol) on subjective effects, behavioural responses and neural functioning in 16-17 year-olds and 26-29 year-olds who regularly use cannabis (0.5-3 days per week).


Eligibility criteria:
inclusion criteria: * adolescents: aged 16-17 * adults: aged 26-29 years * self-reported cannabis use between 0.5 and 3 days/week, averaged over the last 3 months * adults: body mass index (bmi) between 18.5 and 29.9 * adolescents: bmi between 2nd percentile and 98th percentile * self-reported ability to consume approximately half a typical joint of cannabis by themselves within 20 minutes * willing to be cannulated and have four blood samples taken at every acute session * right-handed exclusion criteria: * females: pregnant or breast-feeding * adults: before the age of 18, had a period of 3 or more months when cannabis was used once per week or more frequently. * severe cannabis use disorder (dsm-5) * illicit drug use of any specific drug more than twice per month, averaged over the last 3 months * receiving treatment (pharmacological or psychological) for a mental health problem within the last month * lifetime psychosis * lifetime psychosis of any immediate family member * hypertension (systolic \> 160 or diastolic \> 100) * dependent on tobacco or vaping nicotine (\> 1 on the heaviness of smoking index) * currently taking a psychotropic medication that will likely affect dependent variables or interact with cannabis * any physical or mental health condition, any medication, or any treatment, that the study doctor considers to be an exclusion * mri contraindications * significant asthma or respiratory problems - severity judged clinically * self-reported moderate/severe acute unpleasant effects from cannabis which occur often or always * positive alcohol breathalyser reading at any acute session (rearrange session) * self-reported use of alcohol within 24 hours at any acute session (rearrange session) * self-reported use of illicit drugs (including cannabis) within 72 hours at any acute session (rearrange session) * positive saliva drug screen at any acute session (rearrange session)

Keywords: cannabis marijuana thc cbd adolescence fmri cognition subjective effects psychotomimetic effects
green tea mouthwash on generalized plaque- induced gingivitis

Conditions: Plaque Induced Gingivitis

Summary: this investigation will study the effect of green tea mouthwash as an adjunctive therapy to mechanical treatment on gingival health, and whether it has any side effects. this study also aims at increasing the awareness among health professionals and the community regarding the benefits of natural herbal products such as green tea on oral health, opposed to common chemical products. this may provide an efficient alternative for people who are sensitive to certain chemical products or who have limited sources of income and cannot afford expensive treatment of dental problems.


Eligibility criteria:
inclusion criteria: * patients attending the clinics at the taibah university dental college and hospital (tudch) * age from 18 - 35 years * generalized plaque-induced gingivitis (gbi \> 85%) exclusion criteria: * patients with any systemic diseases * patients under regular medication (e.g. contraceptives, hormone- replacement therapy) * pregnant or breast-feeding patients * smokers * periodontitis patients * patients who received any form of periodontal therapy within the last 6 months * patients who were under antibiotic therapy the past month * patients using regular mouthwash or other chemical plaque control agents (e.g. miswak) except for regular toothpaste (note: toothpastes with specific anti-inflammatory properties are excluded)
a study to evaluate the intratumoral influenza vaccine administration in patients with breast cancer

Conditions: Breast Cancer; Breast Cancer Triple Negative

Summary: this phase 1 study will assess the safety and efficacy (usefulness) of administering 2 doses of seasonal flu vaccine directly into breast cancer tissue (primary tumor), and will study the tumor and whole body response to the vaccine. if the tumor is palpable (able to fee by touch), the vaccine will be administered by a surgeon/oncologist in the outpatient floor - both experienced and trained. if not palpable, the procedure will be done via guided ultrasound by our breast radiologist -- both experienced and trained. women with triple-negative (tnbc) and her2+ types of breast cancer will be eligible for enrollment. up to 18 subjects may be enrolled at rush. successive groups of 3 subjects per breast cancer type will be given increasing doses of vaccine. there are 3 potential dosing groups (half-dose, full dose, and high dose). blood, stool (optional), and tumor tissue samples will be collected and tested. the active participation period is from one week prior to starting chemotherapy through three months post surgery.


Eligibility criteria:
inclusion criteria: * ecog 0-2 * patients must be planning to receive standard of car e neoadjuvant chemotherapy as defined by the most recent version of nccn guidelines (www.nccn.org) * patients must have histologically or cytologically confirmed invasive breast cancer that is either triple-negative or her2+ (regardless of hormone receptor status) exclusion criteria: * patients with any uncontrolled intercurrent illness. * patients who have any underlying medical condition for which, in the investigator's opinion, participation would not be in the best interest of the participant * history of egg allergy * patients currently on anticoagulant therapy, corticosteroids, or immunosuppressive agents * history of allergic reactions attributed to compounds of similar chemical or biologic composition to the seasonal flu vaccine. * history of guillain-barré syndrome

Keywords: breast cancer breast cancer triple negative breast cancer her2+ flu vaccine intratumoral flu vaccine intratumoral vaccine
study for collection of aflibercept data in routine practice

Conditions: Eye Diseases

Summary: the french codex study is designed as a national database to describe, in routine medical practice, functional and anatomical responses to intravitreal aflibercept injection, in a large population of anti-vgef-naïve patients presenting with wet age-related macular degeneration (wamd), central retinal vein occlusion (crvo),branch retinal vein occlusion(brvo), or diabetic macular edema (dme). this national database will gather databases from french private and public ophthalmologic centers.

the retrospective data will be gathered from the first injection of aflibercept for the indications macular edema following branch retinal vein occlusion (brvo) directly by each physician. for each patient, the first injection date of aflibercept is defined as the index date. electronic files from each ophthalmologist, containing patient medical records, will be periodically transmitted according to the milestones of the study with a maximum of 4 transfers (at q2 2016 for the first transfer and then every 9 months thereafter). as each electronic transfer will be independent of each other and as patients' data will be anonymized by physicians before each transfer, data comparisons will be not possible between the four electronic files transfers planned over the study period.

Eligibility criteria:
inclusion criteria: * aged ≥18 years old * anti-vegf (vascular endothelial growth factor) treatment naïve * intravitreal (ivt) aflibercept injection treatment follows the recommendations made within the eylea summary of product characteristics * diagnosed with wamd (wet age-related macular degeneration), macular edema following crvo (central retinal vein occlusion), macular edema following brvo (branch retinal vein occlusion), or dme (diabetic macular edema). exclusion criteria: * who have any contraindications listed in the eylea summary of product characteristics * participating in an investigational program with interventions outside of routine clinical practice.

Keywords: database diabetic macular edema (dme) wet age-related macular degeneration (wamd) retinal diseases optic nerve diseases corneal diseases vision disorders
cetaphil restoraderm effect on young children with atopic dermatitis

Conditions: Atopic Dermatitis

Summary: the purpose of this study is to evaluate the effect of cetaphil® restoraderm® skin restoring moisturizer in reducing the signs and symptoms of very dry atopic skin in young children. subjects with atopic dermatitis (ad) in remission phase will be randomized to receive either cetaphil® restoraderm® skin restoring body wash only, or the same body wash in association with cetaphil® restoraderm® skin restoring moisturizer.

two groups randomized in a ratio of \[1:1\] for a 12-week period five study evaluation were planned: at baseline, week 2, week 4, week8 and week12

Eligibility criteria:
inclusion criteria: * male or female subject, aged 2 to 12 years inclusive * controlled mild to moderate atopic dermatitis with a investigator global assessment score at 0 or 1, within one week after successful treatment with topical corticosteroid. exclusion criteria: * subject presenting bacterial, viral, fungal or parasite skin infection * subject with ulcerated lesions, acne or rosacea * immunosuppression * subject with a wash-out period from baseline for topical treatment less than 8 days for calcineurin inhibitor * subject with a wash-out period from baseline for topical treatment more than 8 days for corticosteroid * subject with a wash-out period from baseline for systemic treatment less than 8 days for anti-histamines, less than 4 weeks for immunomodulators
dual tasking in children with cerebral palsy and healthy children: an eeg study

Conditions: Child Development

Summary: simultaneous execution of motor and cognitive tasks is embedded in the daily life of children. an eeg study will be conducted on healthy children and children with cerebral palsy to study the neural correlates during dual tasking while walking

children will walk at their preferred speed on a treadmill. during dual tasking, they will listen to animals cries and will have to count the number of specified animals cries.

Eligibility criteria:
inclusion criteria: * normal walking for children with cerebral palsy: diplegia or hemiplegia, gmfcs 1 or 2, no botulinium injection since 4 months exclusion criteria: * medical problem
characterization of lv strain patterns in mildly elevated pcwp and pah.

Conditions: Hypertension, Pulmonary Artery; Ventricular Dysfunction, Left

Summary: the purpose of this study is to determine if patients with pulmonary hypertension and mildly elevated heart pressure known as pcwp will exhibit different patterns on echocardiography and that these patterns will predict treatment response to sildenafil, a drug given for this condition.


Eligibility criteria:
inclusion criteria: * patients with new york heart association/world health organization(nyha/who)functional class ii-iii * patients with mean pulmonary artery pressure \>25 mmhg, pulmonary capillary wedge pressure \>15 mmhg ≤18, and pulmonary vascular resistance \>3 wood units * age \>18 and \<80 * stable on antihypertensives and diuretics\>3 months * no evidence of active ischemic heart disease * 6 minute walk distance \>150 meters and \<450 meters exclusion criteria: * - left ventricular ejection fraction \<50% * patients with significant restrictive lung disease (fvc\<60% predicted) and/or significant obstructive lung disease (fev1 \<55% predicted) within 1 year of enrollment * poorly interpretable grey scale echocardiographic images * contraindications to right heart catheterization * nitroglycerin therapy * moderate-severe aortic and mitral valve abnormality * contraindications to submaximal exercise testing

Keywords: pulmonary artery hypertension pulmonary capillary wedge pressure sildenafil echocardiography left ventricular longitudinal wall strain strain rate pre and post medical therapy speckle tracking
cardiovascular risk evaluation and antiretrovirals in hiv

Conditions: Cardiovascular Risk; HIV Infections

Summary: the purpose of the study is to determine the main factors contributing to predicted 10 year cardiovascular risk in an hiv infected cohort, and the role of anti-hiv drug use in altering this risk


Eligibility criteria:
inclusion criteria: * serologically proven hiv infection * attending general hiv outpatient clinic exclusion criteria: * attending a specialist outpatient clinic which might lead to recruitment bias

Keywords: hiv cardiovascular coronary hear disease haart antiretroviral
study of patient outcomes 5 years after partial knee replacement

Conditions: Osteoarthritis, Knee

Summary: the study seeks to evaluate the condition of patients 5 years after having undergone partial knee replacement for localized osteoarthritis of the knee. participating patients will voluntarily undergo detailed evaluation of clinical and radiologic outcomes 5 years after surgery. the aims of the study are to describe the survivorship of the prostheses and the clinical results of patients, and to elucidate and describe the natural history disease of the untreated knee joint compartments after a partial replacement. patients who were operated by the principal investigator 5 years previously will be invited to participate. the study is observational in nature; there is no element of experimentation or test of an intervention.


Eligibility criteria:
inclusion criteria: * all individuals who have undergone unicondylar knee replacement of a single tibio-femoral compartment using ibalance prosthesis (arthrex, inc, lakeland florida) under the care of the principal investigator between december, 2006 and december, 2008 will be invited to participate in the study. exclusion criteria: * there are no restrictions to inclusion in the study based on surgical or medical criteria; however, individuals who are pregnant, incarcerated, less than 18 years of age, or unable to give valid informed consent on their own behalf will be excluded from the study.

Keywords: unicondylar knee arthroplasty partial knee replacement
a study to design a model cohort for analysis of dyslipidemia (mk-0653a-204)

Conditions: Dyslipidemia; Hypercholesterolemia

Summary: this study is being done to provide valid data on the evolution of a cohort of french participants treated with ezetimibe, alone or in combination with a statin, to be used in simulation models for cardiovascular disease (cvd). patterns of drug use, evolution of risk factors for cvd, cardiovascular morbidity and mortality, and goal attainment in low density lipoprotein cholesterol (ldl-c) levels over time will be analyzed.


Eligibility criteria:
inclusion criteria: * resident of continental france * treated by ezetimibe either as monotherapy (ezetrol®), or co-administered with a statin or administered in a fixed combination of ezetimibe and simvastatin (inegy®) * incident treatment with ezetimibe at the time of recruitment into the study exclusion criteria: * unlikely to be followed-up for the next 6 months after recruitment due to a planned change of residence * participating in a clinical trial * unable to read the information letter in french and/or unable to participate in the telephone interview in french
mitraclip nt system post-marketing surveillance study - japan

Conditions: Mitral Regurgitation; Mitral Valve Regurgitation

Summary: the purpose of the mitraclip post-marketing clinical use surveillance study is to observe the frequency, type and degree of adverse device effects and adverse events in order to assure the safety of the new medical device, and to collect safety and efficacy information for evaluating the results of the clinical use.

this study is a prospective, mutli-center, single-arm post-marketing clinical use surveillance study. the surveillance will consecutively register patients with moderate to severe and severe mitral regurgitation (3+ and 4+ mr) in whom a mitraclip implant was attempted. patients registered in the avj-514 clinical trial who received additional mitraclip procedures will be excluded from the surveillance. patients will be evaluated at baseline, procedure, discharge, 30 days, 1 year, 2 years and 3 years in japanese medical centers.

Eligibility criteria:
inclusion criteria: refer to mitraclip ifu exclusion criteria: refer to mitraclip ifu

Keywords: mitral valve regurgitation mitraclip mitraclip nt japan mitraclip nt postmarketing surveillance